Multi-Modal Drug Discovery

Case study highlights

In this case study we show how AI-driven analytics and multi-modal data analysis supported the identification and validation of potential therapeutic targets in oncology. By efficiently analysing data to pinpoint relevant candidate targets and working these through a structured validation process, the approach supported quicker translation into planning for clinical applications. Through optimised resource use, enhanced collaboration and a focus on precision medicine, the client is positioned to make strategic progress in developing targeted therapies for specific patient populations.

The company

A US-based drug development company focused on cancer treatment is working to improve the process of finding and confirming effective therapeutic targets. Their approach combines genetic information, protein studies, medical imaging and patient health records — integration intended to improve the accuracy and efficiency of identifying potential treatment targets. The company's strong emphasis on target identification means resources for bioinformatics and data science are somewhat constrained, with most staff being laboratory scientists.

The challenge

• Integration and analysis of diverse, high-volume data. Combining multi-modal data from genomics, proteomics, imaging and clinical records is difficult due to varying data formats, quality and scales, and demands advanced computational infrastructure while remaining cost-effective.
• Siloed analysis and expertise. Previous attempts to analyse the multi-modal data resulted in teams working in silos, since the data was stored separately due to differing formats and sizes — making it effectively impossible to analyse the combined dataset.
• Identification of relevant features. Extracting features from multi-modal data that correlate with potential therapeutic targets requires advanced feature-selection techniques amid many variables.
• Biological complexity and variability. Correlating multi-modal data to identify potential targets involves deciphering intricate biological interactions and variation across patients or disease subtypes.
• Validation robustness. Ensuring the reliability and reproducibility of identified targets is critical, requiring comprehensive validation processes including cross-validation and external validation against independent datasets.
• Ethical and regulatory considerations. Handling sensitive patient data while complying with regulations such as HIPAA and GDPR adds complexity to data collection, storage and analysis.
• Biological and clinical relevance. Targets need to be clearly connected to disease mechanisms and potential therapeutic interventions, not just statistically distinct.
• Resource constraints. Access to skilled data science and engineering expertise was limited, constraining the speed and efficiency of target identification and validation.

The strategy

Every organisation is unique, and generic solutions fall short of addressing their distinct challenges. Sonrai is built for the complexities of precision medicine, offering tailored support aligned with the client's specific needs. Here's what shaped the client's decision to work with Sonrai:

• Data integration and harmonisation. Sonrai's cloud-based platform integrated all the multi-modal data involved and linked it to additional validation datasets, storing large volumes of data in a scalable, cost-effective way — a key reason Sonrai was chosen for this project.
• Advanced AI analytics. Sonrai's image management and analysis module, alongside code-optional applications, enabled analysis of the unified multi-modal dataset, giving the client's experts access to both the data and the tools to analyse it.
• Robust validation processes. Sonrai's platform supports iterative validation, including cross-validation and external validation against independent datasets, strengthening the robustness and reproducibility of identified targets.
• Biological and clinical contextualisation. Sonrai's multi-modal data analysis combined with domain-specific knowledge helped interpret data in the context of biological mechanisms and clinical relevance, supporting the case that identified targets were meaningfully connected to disease mechanisms.
• Ethical and regulatory compliance. Sonrai's platform incorporates security measures and protocols supporting compliance with healthcare regulations (HIPAA, GDPR), addressing concerns about handling sensitive patient data.
• Resource optimisation. Sonrai's cloud-based infrastructure provided scalable computational power, reducing the need for extensive infrastructure investment and freeing the company to focus resources on R&D.
• Interdisciplinary collaboration. A centralised platform for data analysis supported communication and collaboration between data scientists, biologists and clinicians.
• Iterative, accelerated pipeline. Sonrai's AI technology helped reduce timelines for identifying potential therapeutic candidates, supporting quicker translation of discoveries into clinical development planning.

Results

The collaborative partnership between Sonrai and our client expedited target identification and validation by integrating and analysing multi-modal data. Sonrai's technology supported efficient data use, helping rapidly narrow down potential therapeutic targets and supporting the client's drug development process in oncology.

• Accelerated target identification. AI-driven analytics and a unified data ecosystem expedited identifying potential therapeutic targets by efficiently analysing correlations and patterns within multi-modal data, significantly reducing the time typically required for this phase.
• Improved target validation. The client worked through Sonrai's validation processes on identified targets — iterative validation including cross-validation and external validation against independent datasets, strengthening confidence in the reliability and reproducibility of identified targets.
• Enhanced precision and relevance. Interpreting multi-modal data within the biological and clinical context supported identified targets having strong biological relevance and clinical significance, closely aligned with disease mechanisms and potential therapeutic interventions.
• Optimised resource utilisation. Sonrai's cloud-based infrastructure provided scalable computational power, reducing the burden on in-house resources and freeing focus for research and development.
• Streamlined collaboration and communication. Sonrai supported collaboration among multidisciplinary teams, facilitating communication between data scientists, biologists and clinicians throughout the target identification and validation process.
• Faster translation to clinical applications. Accelerated target identification and validation supported quicker translation of discoveries into clinical development planning, with the potential to speed development of targeted therapies for specific patient populations.
• Enhanced confidence in results. Rigorous validation processes, interpretable results, and attention to ethical and regulatory standards support confidence in the reliability and relevance of identified targets — important for downstream decision-making.
• Strategic advancements in precision medicine. The results from working with Sonrai could help position the drug developer at the forefront of precision medicine — insights from multi-modal data analysis may inform the development of therapies tailored to specific patient groups.